Marina Bobou

Marina Bobou

Auto-generated profile, based on publicly available information

Marina Bobou

Research Department of Clinical, Educational and Health Psychology, University College London, 1-19 Torrington Place, London, England, WC1E 7HB, United Kingdom, 44 20 7612 6143

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 August 2023 in Psychiatry and Clinical Neurosciences
Verified
Journal Article
Open access
NHNikolas Heim
Nikolas Heim
MBMarina Bobou
Marina Bobou
MTMichal Tanzer
Michal Tanzer
PJPaul M. Jenkinson
Paul M. Jenkinson
CSChristiane Steinert
Christiane Steinert
AFAikaterini Fotopoulou
Aikaterini Fotopoulou
Disturbed interoception (i.e., the sensing, awareness, and regulation of internal body signals) has been found across several mental disorders, leading to the development of interoception‐based interventions (IBIs). Searching PubMed and PsycINFO, we conducted the first systematic review of randomized‐controlled trials (RCTs) investigating the efficacy of behavioral IBIs at improving interoception and target symptoms of mental disorders in comparison to a non‐interoception‐based control condition [CRD42021297993]. Thirty‐one RCTs fulfilled inclusion criteria. Across all studies, a pattern emerged with 20 (64.5%) RCTs demonstrating IBIs to be more efficacious at improving interoception compared to control conditions. The most promising results were found for post‐traumatic stress disorder, irritable bowel syndrome, fibromyalgia and substance use disorders. Regarding symptom improvement, the evidence was inconclusive. The IBIs were heterogenous in their approach to improving interoception. The quality of RCTs was moderate to good. In conclusion, IBIs are potentially efficacious at improving interoception for some mental disorders. In terms of symptom reduction, the evidence is less promising. Future research on the efficacy of IBIs is needed.

4 February 2026 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MBMarina Bobou
Marina Bobou
MTMichal Tanzer
Michal Tanzer
ASAlkistis Saramandi
Alkistis Saramandi
CSCaroline Selai
Caroline Selai
AFAikaterini Fotopoulou
Aikaterini Fotopoulou
Dysregulations in interoception have been associated with mental health disorders including eating and somatic symptom disorders. The present study addresses the feasibility and acceptability of a novel, behavioural intervention (InMe) in a healthy sample with low, self-reported interoception. The efficacy of the InMe intervention against an active control arm was tested in a randomised controlled trial (RCT) reported elsewhere, while the feasibility and acceptability of InMe were assessed in parallel and are fully reported here. Participants were randomly assigned to the intervention arm (InMe) or active control arm and stratified according to their self-reported gender and a cut-off score from the Eating Disorders Questionnaire (EDE-Q). Feasibility and accessibility measures included self-report scales and questionnaires, assessor checklists and ratings, as well as behavioural and physiological responses. Data was gathered from a total of 102 participants and encompassed trial recruitment and retention rates, the suitability of measurement tools, as well as the feasibility and acceptability of stressors, interventions and other trial procedures. The study found satisfactory feasibility in recruitment procedures, trial measurement tools, and intervention procedures. Participants perceived the intervention as acceptable, though minor adjustments for trial optimisation were identified. Overall, this feasibility study provided promising evidence regarding the acceptability and feasibility of an interoception based intervention in a RCT context. These findings offer valuable insights particularly for the design of future clinical trials for testing the efficacy of this intervention further in clinical populations.


26 November 2025 in Trials
Verified
Journal Article
Open access
PDF file
JTJemima Thompson
Jemima Thompson
MBMarina Bobou
Marina Bobou
KRKate Roberts
Kate Roberts
STShiva Taheri
Shiva Taheri
SLSharon B. Love
Sharon B. Love
MMMacey L. Murray
Macey L. Murray
Background: Data collected within clinical trials often overlaps with routinely collected Health Systems Data (HSD). There is potential for HSD to reduce burdens for trials and understanding HSD use can help triallists make decisions about using HSD in future trials. However, it is unknown to what extent HSD use has been reported in trial publications, despite the development of guidelines such as ESMO-GROW and CONSORT-ROUTINE extension for reporting HSD use in trials. This study expands on work previously conducted by Lensen and colleagues (Trials 21(1):398, 2020). It aims to provide insights into how HSD use is reported in main result publications that present main trial results, before and after the release of the CONSORT-ROUTINE extension. Methods: This was a systematic review of the reporting of HSD use in primary results publications of trials that accessed HSD between 2017 and 2018. Of 90 trials identified by Lensen and colleagues, those that had published primary outcome results were included in the review. Trials were excluded if (1) primary results were not yet due to be reported; (2) not yet published; (3) they were published prior to June 2017; (4) they were published in 2017, but HSD was accessed in 2018 and (5) the primary publication only reported HSD use in secondary, interim or Study Within a Trial (SWAT) analysis. Eligible publications were identified using ISRCTN, ClinicalTrials.gov, EU Clinical Trials Registries, PubMed and Embase. The reporting of HSD use was compared against expectations for reporting outlined in the CONSORT-ROUTINE extension. Results: Forty-nine primary publications from 46 trials were included in the review . Overall, none of the included publications reported all the information suggested in the CONSORT-ROUTINE. However, there has been an improvement in the reporting of HSD use, since the publication of the CONSORT-ROUTINE guidelines. Conclusions: Reporting of HSD use has improved over time. However, it still does not meet the expectations set out in the CONSORT-ROUTINE extension. Triallists should be encouraged to provide further information in publications about the use of HSD as per the CONSORT-ROUTINE extension guidelines. This would allow greater transparency in reporting, facilitating effective HSD use in future trials.

24 March 2025 in Research Square
Verified
Preprint
Open access
PDF file
JTJemima Thompson
Jemima Thompson
MBMarina Bobou
Marina Bobou
KRKate Roberts
Kate Roberts
STShiva Taheri
Shiva Taheri
SLSharon B. Love
Sharon B. Love
MMMacey L. Murray
Macey L. Murray
Background : Data collected within clinical trials often overlaps with routinely collected Health Systems Data (HSD). There is potential for HSD to reduce burdens for trials and understanding HSD use can help triallists make decisions about using HSD in future trials. However, it is unknown to what extent HSD use has been reported in trial publications, despite the development of guidelines such as ESMO-GROW and CONSORT-ROUTINE extension for reporting HSD use in trials. This study expands on work previously conducted by Lensen and colleagues (1). It aims to provide insights into how HSD use is reported in main result publications that present main trial results, before and after release of the CONSORT-ROUTINE extension. Methods : This was a systematic review of the reporting of HSD use in primary results publications of trials that accessed HSD between 2017-2018. Of 90 trials identified by Lensen and colleagues, those that had published primary outcome results were included in the review. Trials were excluded if (1) primary results were not yet due to be reported; (2) not yet published; (3) they were published prior to June 2017; (4) they were published in 2017, but HSD was accessed in 2018 and (5) the primary publication only reported HSD use in secondary, interim or Study Within a Trial (SWAT) analysis. Eligible publications were identified using ISRCTN, ClinicalTrials.gov, EU Clinical Trials Registries, PubMed and Embase. The reporting of HSD use was compared against expectations for reporting outlined in the CONSORT-ROUTINE extension. Results : Forty-nine primary publications from 46 trials were included in the review. Overall, none of the included publications reported all the information suggested in the CONSORT-ROUTINE. However, there has been an improvement in the reporting of HSD use, since the publication of the CONSORT-ROUTINE guidelines. Conclusions : Reporting of HSD use has improved over time. However, it still does not meet the expectations set out in the CONSORT-ROUTINE extension. Triallists should be encouraged to provide further information in publications about the use of HSD as per the CONSORT-ROUTINE extension guidelines. This would allow greater transparency in reporting, facilitating effective HSD use in future trials.

12 March 2026 in Journal of Participatory Medicine
Verified
Journal Article
Open access
MBMarina Bobou
Marina Bobou
MTMichal Tanzer
Michal Tanzer
ASAlkistis Saramandi
Alkistis Saramandi
CSCaroline Selai
Caroline Selai
PJPaul M Jenkinson
Paul M Jenkinson
AFAikaterini Fotopoulou
Aikaterini Fotopoulou
Background: Patient and public involvement (PPI) is crucial for enhancing research quality and relevance and addressing health inequalities. PPI ensures that studies tackle relevant and meaningful questions, as there is a recognized need by the research community to document and share PPI studies to advance the field and encourage the adoption of such activities. Objective: The study aimed to provide a detailed report on the PPI activities undertaken to develop and implement a randomized controlled trial of a novel therapeutic tool designed to increase interoception and metacognition (ie, the Interoceptive Insight and Metacognitive Efficacy beliefs [InMe] trial). Methods: The InMe trial integrated insights from experts by experience, as well as from clinical and academic experts. This collaborative approach resulted in the development of a comprehensive trial across 4 main stages—design, delivery, results interpretation, and future planning. Results: Here, we highlighted the unique insights and the added value in incorporating PPI activities into our trial development and implementation, while reporting challenges and shortcomings that were identified throughout this process. Conclusions: PPI activities within the InMe trial led to meaningful changes, while collaborators expressed satisfaction and increased interest in interoception research. Further improvements on how to best support experts by experience when sharing their experiences were also identified.